ASLAN Pharmaceuticals Limited, a clinical-stage oncology-focused biopharmaceutical company, engages in the development of drugs for prevalent cancers. It targets diseases that are prevalent in Asia, and orphan indications in the United States and Europe. The company's lead program, varlitinib, is a reversible small molecule pan-human epidermal growth factor receptor, or pan-HER, inhibitor that targets the human epidermal growth factor receptors HER1, HER2, and HER4.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone65-6222-4235
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$11.55 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date11/14/2019 (Estimated)
OptionableNot Optionable
ASLAN PHARMACEU/ADR (NASDAQ:ASLN) Frequently Asked Questions
What is ASLAN PHARMACEU/ADR's stock symbol?
ASLAN PHARMACEU/ADR trades on the NASDAQ under the ticker symbol "ASLN."
How were ASLAN PHARMACEU/ADR's earnings last quarter?
ASLAN PHARMACEU/ADR (NASDAQ:ASLN) released its earnings results on Tuesday, August, 13th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.20) by $0.05. View ASLAN PHARMACEU/ADR's Earnings History.
When is ASLAN PHARMACEU/ADR's next earnings date?
What price target have analysts set for ASLN?
1 brokerages have issued 1 year price objectives for ASLAN PHARMACEU/ADR's stock. Their predictions range from $9.00 to $9.00. On average, they anticipate ASLAN PHARMACEU/ADR's stock price to reach $9.00 in the next year. This suggests a possible upside of 361.5% from the stock's current price. View Analyst Price Targets for ASLAN PHARMACEU/ADR.
What is the consensus analysts' recommendation for ASLAN PHARMACEU/ADR?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ASLAN PHARMACEU/ADR in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ASLAN PHARMACEU/ADR.
Has ASLAN PHARMACEU/ADR been receiving favorable news coverage?
News articles about ASLN stock have been trending negative this week, InfoTrie reports. InfoTrie ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. ASLAN PHARMACEU/ADR earned a media sentiment score of -2.9 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the next several days. View News Stories for ASLAN PHARMACEU/ADR.
Who are some of ASLAN PHARMACEU/ADR's key competitors?
Some companies that are related to ASLAN PHARMACEU/ADR include Aratana Therapeutics (PETX), Syndax Pharmaceuticals (SNDX), Chiasma (CHMA), Xenon Pharmaceuticals (XENE), Spero Therapeutics (SPRO), Affimed (AFMD), Athersys (ATHX), Molecular Templates (MTEM), Stealth BioTherapeutics (MITO), Galectin Therapeutics (GALT), Mirum Pharmaceuticals (MIRM), Fulcrum Therapeutics (FULC), Bicycle Therapeutics (BCYC), CannTrust (CTST) and Calithera Biosciences (CALA).
What other stocks do shareholders of ASLAN PHARMACEU/ADR own?
Who are ASLAN PHARMACEU/ADR's key executives?
ASLAN PHARMACEU/ADR's management team includes the folowing people:
- Dr. Carl Alan Jason Morton Firth, Chairman & CEO (Age 46)
- Mr. Kiran Asarpota, VP of Fin. (Age 40)
- Charlie Hsu, Investor Relations Director
- Mr. Ben Goodger, Gen. Counsel (Age 56)
- Chi-Chin Wang, IR & Corp. Devel. Director
When did ASLAN PHARMACEU/ADR IPO?
(ASLN) raised $60 million in an IPO on Friday, May 4th 2018. The company issued 7,500,000 shares at $8.05 per share. Leerink Partners and Piper Jaffray acted as the underwriters for the IPO and BTIG, H.C. Wainwright and CLSA were co-managers.
Who are ASLAN PHARMACEU/ADR's major shareholders?
ASLAN PHARMACEU/ADR's stock is owned by many different of institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (1.34%), Platinum Investment Management Ltd. (1.30%) and FNY Investment Advisers LLC (0.04%).
Which institutional investors are selling ASLAN PHARMACEU/ADR stock?
ASLN stock was sold by a variety of institutional investors in the last quarter, including FNY Investment Advisers LLC and Baillie Gifford & Co..
Which institutional investors are buying ASLAN PHARMACEU/ADR stock?
ASLN stock was acquired by a variety of institutional investors in the last quarter, including Platinum Investment Management Ltd..
How do I buy shares of ASLAN PHARMACEU/ADR?
Shares of ASLN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is ASLAN PHARMACEU/ADR's stock price today?
One share of ASLN stock can currently be purchased for approximately $1.95.
How big of a company is ASLAN PHARMACEU/ADR?
ASLAN PHARMACEU/ADR has a market capitalization of $62.50 million and generates $11.55 million in revenue each year. The company earns $-42,190,000.00 in net income (profit) each year or ($1.40) on an earnings per share basis. View Additional Information About ASLAN PHARMACEU/ADR.
What is ASLAN PHARMACEU/ADR's official website?
How can I contact ASLAN PHARMACEU/ADR?
ASLAN PHARMACEU/ADR's mailing address is 83 CLEMENCEAU AVENUE 12-03 UE SQUARE, SINGAPORE U0, 239920. The company can be reached via phone at 65-6222-4235 or via email at [email protected]
MarketBeat Community Rating for ASLAN PHARMACEU/ADR (NASDAQ ASLN)
MarketBeat's community ratings are surveys of what our community members think about ASLAN PHARMACEU/ADR and other stocks. Vote "Outperform" if you believe ASLN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ASLN will underperform the S&P 500 over the long term. You may vote once every thirty days.
